CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
40 hedge funds and large institutions have $61M invested in CTI BioPharma Corp. (DE) Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 13 closing their positions.
118% more capital invested
Capital invested by funds: $28M → $61M (+$32.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
15% less funds holding
Funds holding: 47 → 40 (-7)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$19.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$16M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.89M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.82M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$975K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$668K |
| 2 |
Jane Street
New York
|
-$233K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$230K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$183K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$181K |
CTIC Hedge Fund Activity: Q2 2017 in Review
40 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2017, worth a combined $61M — up 118% from $28M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CTIC and 6 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $19.5M. The largest seller was Millennium Management, exiting entirely with an estimated $668K sold.
- 40 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2017, down from 47 in Q1 2017.
- Funds reported $61M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2017, up 118% quarter-over-quarter.
- 6 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2017 and 13 closed out, a net change of -7 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2017 was OrbiMed, an estimated $19.5M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2017 was Millennium Management, an estimated $668K sold.
Based on aggregated 13F filings for Q2 2017.